Mark E. Strome - Dec 31, 2024 Form 5 Insider Report for Zivo Bioscience, Inc. (ZIVO)

Role: 10%+ Owner
Signature: /s/ Mark E. Strome
Stock symbol: ZIVO
Transactions as of: Dec 31, 2024
Transactions value $: $253,200
Form type: 5
Date filed: 1/23/2025, 07:48 PM
Previous filing: Jun 20, 2024
Next filing: Jan 21, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZIVO	Common Stock	Purchase	$253K	+30K	+8.14%	$8.44	399K	Aug 27, 2024	By entity	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZIVO	Common Stock Purchase Warrant	Purchase	$0	+3K	+7.29%	$0.00	44.2K	Aug 27, 2024	Common Stock	$3K	$8.44	By entity	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are owned directly by Strome Mezzanine Fund II, LP ("SMF II).
F2	Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the "Reporting Persons") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF under Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act").
F3	Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.